BIRICODAR
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 1998 (NCT00003847)
Timeline
1990s
- Jan 1, 1998
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Multidrug resistance protein 1aINHIBITOR
MDR1A inhibitor
Multidrug resistance-associated protein 1 inhibitor
- P-glycoprotein 1INHIBITOR
P-glycoprotein 1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
COc1cc(C(=O)C(=O)N2CCCC[C@H]2C(=O)OC(CCCc2cccnc2)CCCc2cccnc2)cc(OC)c1OC- Mol. weight
- 603.72 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL350775 ↗
- ChEMBLCHEMBL2104406 ↗
Also known as
- biricodar
- biricodar
- biricodar
- biricodar
- biricodar
- biricodar
- biricodar dicitrate
- biricodar dicitrate
- biricodar dicitrate
- biricodar dicitrate
- biricodar dicitrate
- incel
- incel
- n-(2-oxo-2-(3,4,5-trimethoxyphenyl)acety)piperidine-2-carboxylic acid 1,7-bis(3-pyridyl)-4-heptyl ester
- vx 710
- vx 710
- vx-710
- vx-71o-3
- vx-71o-3
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00003847 | Phase 2 | Dec 1, 1998 | Vertex |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vertex | For profit | 1 | 1 | 1 | 1998 |
1 organizations
Page 1 / 1